OUTCOMES BY PROSTATE-SPECIFIC ANTIGEN LEVEL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY AND IMPLICATIONS FOR CLINICAL PRACTICE

被引：0
|
作者：
Huebner, Tamara [1 ]
Williams, Monique [2 ]
Shore, Neal [3 ]
El-Chaar, Nader [4 ]
Russell, David [5 ]
Armstrong, Andrew [6 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[2] Leidos Biomed Res Inc, Bethesda, MD USA
[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[4] Astellas Pharma US, Northbrook, IL USA
[5] Pfizer Inc, New York, NY USA
[6] Duke Canc Inst, Durham, NC USA
来源：
ONCOLOGY NURSING FORUM | 2023年 / 50卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P379
引用
收藏
页数：2
相关论文
共 50 条
  • [1] IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY
    Shore, Neal D.
    Crawford, E. David
    Szmulewitz, Russell Z.
    Petrylak, Daniel
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Baron, Benoit
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF UROLOGY, 2020, 203 : E249 - E250
  • [2] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
    von Bueren, Moritz
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
  • [3] Seven- Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel
    Harshman, Lauren C.
    Chen, Yu-Hui
    Liu, Glenn
    Carducci, Michael A.
    Jarrard, David
    Dreicer, Robert
    Hahn, Noah
    Garcia, Jorge A.
    Hussain, Maha
    Shevrin, Daniel
    Eisenberger, Mario
    Kohli, Manish
    Plimack, Elizabeth R.
    Cooney, Matthew
    Vogelzang, Nicholas J.
    Picus, Joel
    Dipaola, Robert
    Sweeney, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 376 - +
  • [4] Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer
    Nagata, Yujiro
    Matsukawa, Takuo
    Tomisaki, Ikko
    Fujimoto, Naohiro
    ANTICANCER RESEARCH, 2022, 42 (02) : 1107 - 1114
  • [5] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, Christopher J.
    Martin, Andrew J.
    Stockler, Martin R.
    Begbie, Stephen
    Chi, Kim N.
    Chowdhury, Simon
    Coskinas, Xanthi
    Frydenberg, Mark
    Hague, Wendy E.
    Horvath, Lisa G.
    Joshua, Anthony M.
    Lawrence, Nicola J.
    Marx, Gavin M.
    McCaffrey, John
    McDermott, Ray
    McJannett, Margaret
    North, Scott A.
    Parnis, Francis
    Parulekar, Wendy
    Pook, David W.
    Reaume, M. Neil
    Sandhu, Shahneen K.
    Tan, Alvin
    Tan, Thean Hsiang
    Thomson, Alastair
    Tu, Emily
    Vera-Badillo, Francisco
    Williams, Scott G.
    Yip, Sonia
    Zhang, Alison Y.
    Zielinski, Robert R.
    Davis, Ian D.
    EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
  • [6] KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer
    Gratzke, Christian
    Kwiatkowski, Mariusz
    Giorgi, Ugo De
    Martins da Trindade, Karine
    De Santis, Maria
    Armstrong, Andrew J.
    Niu, Cuizhen
    Liu, Yingjie
    Poehlein, Christian Heinrich
    FUTURE ONCOLOGY, 2022, 18 (37) : 4079 - 4087
  • [7] Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
    Sweeney, C. J.
    Martin, A. J.
    Stockler, M. R.
    Begbie, S.
    Chi, K. N.
    Chowdhury, S.
    Coskinas, X.
    Frydenberg, M.
    Hague, W. E.
    Horvath, L. G.
    Joshua, A. M.
    Lawrence, N. J.
    Marx, G. M.
    McCaffrey, J.
    McDermott, R.
    McJannett, M.
    North, S. A.
    Parnis, F.
    Parulekar, W.
    Pook, D. W.
    Reaume, M. N.
    Sandhu, S. K.
    Tan, A.
    Tan, T. H.
    Thomson, A.
    Tu, E.
    Vera-Badillo, F.
    Williams, S. G.
    Yip, S.
    Zhang, A. Y.
    Zielinski, R. R.
    Davis, I. D.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1519 - 1520
  • [8] Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
    Stenzl, A.
    Krivoshik, A.
    Baron, B.
    Hirmand, M.
    Armstrong, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
    Jimenez, Natalia
    Reig, Oscar
    Marin-Aguilera, Mercedes
    Aversa, Caterina
    Ferrer-Mileo, Laura
    Font, Albert
    Rodriguez-Vida, Alejo
    Angel Climent, Miguel
    Cros, Sara
    Chirivella, Isabel
    Domenech, Montserrat
    Figols, Mariona
    Gonzalez-Billalabeitia, Enrique
    Jimenez Peralta, Daniel
    Rodriguez-Carunchio, Leonardo
    Garcia-Esteve, Samuel
    Garcia de Herreros, Marta
    Ribal, Maria J.
    Prat, Aleix
    Mellado, Begona
    CANCERS, 2022, 14 (19)
  • [10] Time to Prostate-Specific Antigen Nadir Independently Predicts Overall Survival in Patients Who Have Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen-Deprivation Therapy
    Choueiri, Toni K.
    Xie, Wanling
    D'Amico, Anthony V.
    Ross, Robert W.
    Hu, Jim C.
    Pomerantz, Mark
    Taplin, Mary-Ellen
    Kantoff, Philip W.
    Sartor, Oliver
    Oh, William K.
    CANCER, 2009, 115 (05) : 981 - 987
12345